AstraZeneca on Friday reported $1.05bn in third-quarter Covid vaccine sales as the not-for-profit drug added 1% to earnings in the period, while the company reiterated annual forecasts for 2021.
The company said it was now expecting to progressively transition the vaccine to “modest profitability” as new orders are received.
Vaccine sales in the final quarter were expected to be a blend of original pandemic agreements and new orders, with the large majority coming from pandemic agreements.
Third-quarter revenue rose 50% to $9.8bn and by 32% to $25.4bn for the year to date. Core earnings per share rose 14% to $1.08.
